Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) receives $2.2 million R&D cash rebate

Australian oncology-focused biotechnology company, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has received a $2.2 million R&D cash rebate.

The ASX listed company is pleased to confirm they received $2,191,257.95 from the Australian Taxation Office under the R&D tax Incentive Program for the financial year ending 30 June 2018.

Kazia CEO, Dr James Garner, said: ““The R&D tax rebate is an important, non-dilutive source of funding for the Company.”

“The amount is consistent with the expectations laid out in our financial reports, and the funds will be invested in progressing our two clinical programs.”

“This is an important year for Kazia, with multiple data read-outs anticipated in the near future.”

 

About Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.

Register Interest